Biosimilars
Biosimilars/Peptides
Aflibercept
Form: Vial
THERAPEUTIC AREA: Ophtalmology
Adalimumab
Form: PFS/AI
THERAPEUTIC AREA: Rheumatology
BV-GLP1-01
Form: PFS
THERAPEUTIC AREA: Diabetes
Denosumab
Form: PFS
THERAPEUTIC AREA: Rheumatology
Denosumab
Form: PFS
THERAPEUTIC AREA: Rheumatology
Dupilumab
Form: PFS/AI
THERAPEUTIC AREA: Dermatology / Immunology
Golimumab
Form: PFS/AI
THERAPEUTIC AREA: Rheumatology
Guselkumab
Form: PFS/AI
THERAPEUTIC AREA: Dermatology / Immunology
Ixekizumab
Form: PFS/AI
THERAPEUTIC AREA: Dermatology / Immunology
Liraglutide
Form: AI (Prefilled Pen)
THERAPEUTIC AREA: Diabetes
Omalizumab
Form: Vial/PFS
THERAPEUTIC AREA: Respiratory
Pembrolizumab
Form: Vial/Lyo Powder
THERAPEUTIC AREA: Oncology
Teriparatide
Form: AI (Pen)
THERAPEUTIC AREA: Rheumatology
Ustekinumab
Form: Vial
THERAPEUTIC AREA: Dermatology / Immunology
Vedolizumab
Form: Lyo Powder
THERAPEUTIC AREA: Gastroenterology
GlobalOne Healthcare Holding
In addition to licensing, the organization is committed to expanding market presence and contract manufacturing for operating companies across the Middle East, Africa, and beyond. This can facilitate the distribution of important healthcare products to regions where they may not be readily available, improving access to care and promoting better health outcomes. Through its commercial partners, the organization can also leverage local knowledge and expertise to navigate the complexities of these markets and ensure the successful introduction of new products.
Finally, the organization recognizes the importance of investing in late-stage biotech and health/medtech startups to expand its healthcare portfolio globally. By supporting the development of promising new products and technologies, the organization can contribute to the advancement of healthcare and improve outcomes for patients around the world. These investments can also generate returns for the organization and its partners, helping to fund future innovation and growth. Overall, the organization’s mandate reflects a commitment to driving innovation, improving access to care, and promoting better health outcomes for all.